The TLR7 agonist imiquimod, approved for the topical treatment of squamous and basal cell carcinoma, was reported to be safe also in the treatment of melanoma and skin lesions of metastatic breast cancer, enhancing accumulation of immune cells in the lesions [51]. Here, TLR7 is linked to melanoma.